How to Evaluate a GLP-1 Provider in 2026: Seven Checks
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Updated August 25, 2026. Almost everything in the original version of this guide has changed since it originally published in October 2025. The shortages that made mass compounding accessible are changing, compounded isn't automatically the cheaper option anymore, and the FDA has sent 113 warning letters to telehealth companies since September 2025. As always, combine this by checking existing patient reviews, understanding the full plan offering, and pricing beyond your initial signup fee to know if the provider is a good fit for you.
If you need a hand sorting through your options, reach out to the team here - we're always available to help.
1. Find out who actually operates the company
Do this first. Most brands you meet in an ad are storefronts running on rented infrastructure, so the prescriber, the pharmacy and the software may all belong to someone else.
Open the terms of service and search for "LLC," "Inc." or "professional corporation." That entity is who you'd actually have a dispute with. If a different company is named as providing medical services, that's your prescriber's employer rather than the brand. None of the checks below work until you know these names, which is why this replaced consumer reviews as check one.
2. Confirm the pharmacy is licensed in your state
A mail-order pharmacy shipping into your state generally needs a non-resident license there. Ask which pharmacy will fill your prescription before you pay, then verify it yourself.
The FDA maintains a directory of every state board database and states the rule plainly: "If your online pharmacy is not listed, you should not use that pharmacy" (FDA). One usability note from Florida's system: choose Pharmacy as the profession, search the business name, then read the Qualifications field, which is where "Non-Resident" appears.
If it's an outsourcing facility, check the FDA's weekly list too, which shows the last inspection date and whether a Form 483 was issued (FDA registered outsourcing facilities). Registration is self-submitted, so being listed isn't an endorsement. Our pharmacy licensing guide walks through the whole process.
3. Check the company's federal enforcement record
This is new since the last version, and it matters more than star ratings.
The FDA has issued three batches of warning letters to telehealth companies over compounded GLP-1 marketing: 58 letters dated September 9, 2025, then 30 dated February 20, 2026 and announced that March (FDA), then 25 dated June 8, 2026. Search your provider's name in the warning letter database (FDA warning letters). The FDA's own caveat matters: what a letter describes "may have been subject to subsequent interaction between FDA and the letter recipient," so it isn't proof of current wrongdoing.
The agency also publishes what telehealth companies may and may not claim (FDA guidance for telehealth companies). Two specific claims to treat as red flags: any implication that a compounded product is the same as an approved one, and the phrase "FDA-approved pharmacy." The FDA has stated that the FD&C Act "does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities."
4. Ask what the compounded product's legal basis is
This is the biggest change since 2025, and most competing guides haven't caught up.
The FDA determined the tirzepatide shortage resolved on December 19, 2024 and the semaglutide injection shortage resolved on February 21, 2025, and all enforcement-discretion periods for compounders ended by May 2025 (FDA). The agency's reasoning: "When a drug shortage is resolved, FDA generally considers the drug to be commercially available."
For outsourcing facilities, the FDA states that "tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list," which removes both lawful triggers for compounding them from bulk. For a 503A pharmacy it isn't banned outright, but it has to survive the essentially-a-copy restriction, which needs a prescriber to determine and document that the compounded version contains a change producing a significant difference for an identified individual patient. The FDA has said a semaglutide plus B12 combination may count as essentially a copy where strengths sit within 10% of the approved product.
So don't ask whether a provider offers compounded medication. Ask what documented, patient-specific reason exists for yours. A provider selling standard doses to everyone is describing something without a clear basis. Our 503A versus 503B explainer covers the two pathways. This may also mean you don’t get the exact dose on your vial you may have gotten before, so instead of 5 mg/week on the vial, it’s 7.15 mg/week, and the units you take will amount to the same strength.
One more thing to ask about continuity. The FDA proposed in May 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need (FDA). The comment period closed July 30, 2026 (Federal Register), and no final determination had been issued as of today. It's a notice process rather than rulemaking, so watch the bulks list page (FDA 503B bulks list). We are tracking it in our coverage of the proposal.
5. Ask where the active ingredient comes from
Finished-product testing is only half the question, and this check didn't exist in the 2025 version.
The FDA now detains foreign GLP-1 active ingredient shipments by default unless the firm is on a Green List. In the alert it published, the agency reports evaluating 48 GLP-1 API sites and finding 21% noncompliant, and describes "a pattern of sites that register as GLP-1 API manufacturers, offer GLP-1 APIs for import, refuse to answer FDA's requests for records, and then deregister, all within a short period of time" (FDA Import Alert 66-80).
The key point in the same document is the one to carry into a conversation: 503A compounders are exempt from the requirement to ensure the active ingredient meets specifications for impurities or potency, so quality problems in the raw material "would not be adequately controlled for or monitored" downstream. Ask who supplies the ingredient, and ask for a certificate of analysis for your batch. Not all pharmacies will be able to provide this for everyone (given the shipping and paperwork tax), but they should be able to speak to the safety testing of the medication.
6. Ask what clinical oversight you actually get
Don't ask whether a provider is thorough. Ask for specifics, because the market norm is a questionnaire.
Six questions that separate real oversight from a form:
- Will I speak with a licensed clinician before the first prescription, and is that person licensed in my state?
- Who reviews my labs, if any are required? Will labs be paid for, cash-pay only, or covered by my insurance?
- What is the titration protocol, and who decides when I move up?
- Who do I reach at 2am with severe vomiting, and is it a clinician or a chat agent?
- What exactly does your nutrition support include (if this is offered)? Ask for the format. Unlimited dietitian calls and an emailed PDF often get marketed with the same phrase.
- Can you tell me my prescriber's name and license number?
Verify that last one. Physicians and physician assistants are searchable through the Federation of State Medical Boards (DocInfo), but it doesn't cover nurse practitioners, who write a large share of telehealth prescriptions. For an NP, use your state board of nursing or Nursys (Nursys). This information should also be on your medication vial.
7. Compare the real total cost, including brand
The old assumption that compounded is the budget option doesn't hold automatically now, and this check is the one most likely to save you money.
Brand self-pay prices as published by the manufacturers: Wegovy injection is $349 a month across 0.25 to 2.4 mg, and the Wegovy pill starts at $149 a month for 1.5 mg (NovoCare price guide). Zepbound runs $299 for 2.5 mg and $399 for 5 mg, with higher doses at $449 only if you refill within 45 days, otherwise up to $699. Foundayo starts at $149 (Lilly). Keep in mind these prices are at the time of writing, so may change. Insurance also may change the price you pay at checkout.
Three caveats. Each of those is a revocable savings-program price rather than a list price, most carry an expiry date, and several need a refill inside 45 days. You can also buy direct through the manufacturers' own channels (NovoCare Pharmacy)(LillyDirect), which removes a telehealth membership fee entirely, but you also lose out on insurance navigation help and additional services (like group coaching or provider support).
If you are on Medicare, check the GLP-1 Bridge first. It runs from July 1, 2026 through December 31, 2027 at a $50 monthly copay, covers Foundayo tablets, Wegovy injection and tablets, and the Zepbound KwikPen only, and needs prior authorization for the first fill (CMS). Eligibility is narrow. We covered what to do when a claim bounces in our Bridge article.
When you price a compounded option against these, add the membership fee and read the cancellation terms first. If you want a true comparison, answer a few questions with our provider survey to see the breakdown and your full provider options.
Final Takeaway
Start with who operates the company, because everything else depends on it. Then verify the pharmacy's license in your state, search the warning letter database, and ask what documented patient-specific reason exists for a compounded product now that the shortages are over. If a provider won't answer, that's an answer.
Price brand against compounded before assuming compounded wins, and check the Medicare Bridge if it applies to you. If you'd rather not work through all seven alone, our provider survey matches you on your state, your budget and how much clinical support you want.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
Do GLP-1s reduce drinking? A 2026 trial says yes for people with obesity, but two trials missed their goal. What the evidence really shows.
2027 marketplace enrollment runs November 1 to January 15. December 15 is the cutoff for coverage that starts January 1.
The FDA proposed limiting large-scale compounded GLP-1s. See what is actually being decided and which pathway stays open.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.